HEOR Case Studies
Health Analytics’ scientific team regularly contributes articles to trade and peer-reviewed publications. Our publications and presentations are just some examples of the many pertinent resources our company provides for clients, peers, and the healthcare community.
CASE STUDY #1
In an increasingly dynamic and complex health care environment, and with reform on the horizon, both quality of care and cost of care are national issues. Regulatory pressures, quality of care concerns, and access challenges are all business imperatives that demand sound, actionable intelligence and evidence-based solutions. Moreover, you may not have the information you want and need to maximize emerging opportunities.
You need clear, useful scientific information that offers practical, targeted solutions to your problems. Our customized solutions provide specific action steps and support you in communicating to stakeholders. Here are some examples of how Health Analytics has helped other businesses like yours.
A pharmaceutical company with a behavioral health portfolio sought to improve market penetration of their new once-monthly injectable product. Though the product would be more costly than oral product in the market, Health Analytics believed that patient-treatment matching might allow them to demonstrate value to payors by focusing on the most appropriate patient population.
- Characterize the most appropriate patients for a once-monthly injectable treatment.
- Demonstrate for payors the product’s value for their members.
The Health Analytics Solutions
- Health Analytics identified the most appropriate patient population based on modeling using a single payor data set. To build the model, Health Analytics collaborated with the clinical leadership of a large national health plan and the manufacturer. The model was validated based on medical cost offset.
- Leveraging expertise in HEOR analytics, a facile ability to work with various data sets, and content matter experts, health Analytics uncovered two extraordinary findings:
- In this treatment class, there is no evidence for incremental benefit above 60% compliance, whereas, the medical community typically considers 80% or above to be an optimal compliance rate for pharmaceutical products.
- A subgroup of intermittently compliant patients contributed the greatest expense to payors.
- As a result, Health Analytics concluded that the once-monthly injectable regimen offered the greatest value to patients with compliance of less than 60% and those that are intermittently compliant.
- Because of the strong relationship between Health Analytics and the health plan, a subpopulation of patients was revealed that aligned with the optimal use of the product.
- Although the product is more expensive than oral alternatives, medical cost savings were documented. This enabled a strong value story for the product’s use in a specific subpopulation.
- Contact us for a copy of the peer-reviewed publications of these results.
“We wanted to improve patient treatment outcomes by creating a patient support program to compliment our best-in-class pharmacotherapy. Health Analytics evaluated the outcomes-to-ROI link, and then helped us refine the concept and launch a national program that provided the best outcomes improvement for a reasonable investment. Throughout the process, HA provided the data and analysis we needed to make our case to internal and external decision makers, and ultimately they delivered results.“
Director of Marketing, New Product Development